BTK and B-cell chronic lymphocytic leukemia: Both are currently in phase 1 studies with NX-2127 already demonstrating clinical responses in heavily pretreated (median 6 prior therapies) patients with CLL, including those with BTK mutations resistant to both covalent and noncovalent BTKis [71].